Atossa Therapeutics (NASDAQ:ATOS) Stock, Quote.Headers.trade-ideas

Atossa Therapeutics

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Redcliffe,,Queensland,,Australia,-,May,14,2018:,Domino's,Pizza,Store

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ATOS

KRYS

PLAY

SUPN

Domino&#39;s Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday

Screenshot 2024-04-01 at 9.57.34 PM

Biotech

General

This Biotech Works On All Phases Of Breast Cancer, From Prevention To Post Surgery

This Drug Developer Is Dedicated To “Transforming The Breast Cancer Paradigm”

Penny Stocks

Interview

Dr. Steven Quay MD, PhD, President &amp; CEO of Atossa Therapeutics Inc. (NASDAQ: ATOS) was recently interviewed by Benzinga.

This Drug Developer Is Dedicated To &#34;Transforming The Breast Cancer Paradigm&#34;

Atossa Therapeutics Inc

Atos SE

ATOS ORIGIN SA UNSP/ADR by Atos Origin SA

Insider Trades

ADBE

Adobe CFO Daniel Durn Reports Open Market Sale Of 4,500 Shares at $515.23/Share And 2,000 Shares at $515.90/Share On September 17

<p>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) (&quot;Chewy&quot;), a trusted destination for pet parents and partners everywhere, announced today the commencement of an underwritten offering of $500 million of shares of its Class A common stock, par value $0.01 per share, by Buddy Chester Sub LLC (the &quot;Selling Stockholder&quot;), which is an entity affiliated with funds advised by BC Partners Advisors LP (&quot;BC Partners&quot;), Chewy&#39;s largest shareholder (the &quot;Offering&quot;). The Selling Stockholder intends to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of Class A common stock. Chewy will not sell any shares of its Class A common stock in the Offering and will not receive any proceeds from the sale of the shares of Class A common stock being offered by the Selling Stockholder. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed.</p>
<p>In addition, Chewy has agreed to purchase from the Selling Stockholder $300 million of Chewy&#39;s Class A common stock at a price per share equal to the per share purchase price to be paid by the underwriters in the Offering specified above (the &quot;Concurrent Repurchase&quot;). The Concurrent Repurchase was approved by a special committee of Chewy&#39;s Board of Directors, consisting solely of independent and disinterested directors not affiliated with BC Partners. The repurchased shares will be cancelled and retired upon completion of the Concurrent Repurchase. The Concurrent Repurchase is being executed separately from the Company&#39;s existing $500 million share repurchase program authorized on May 24, 2024, which will be unaffected by this transaction. The Concurrent Repurchase is expected to be consummated concurrently with the Offering. The Offering is not conditioned upon the closing of the Concurrent Repurchase, but the Concurrent Repurchase is conditioned upon the closing of the Offering.</p>


Offerings

CHWY

Chewy Announces A $500M Underwritten Offering Of Shares By Its Largest Shareholder, Buddy Chester Sub LLC; Chewy Will Concurrently Repurchase $300M Of Its Stock From The Selling Stockholder At The Offering Price, Separate From Its Existing Share Repurchase Program

WIIM

Chewy shares are trading lower after the company announced the public offering of shares by a selling stockholder and a concurrent share repurchase.

ANGO

AngioDynamics Initiates RECOVER-AV Clinical Trial Of AlphaVac F18⁸⁵ System In Pulmonary Embolism And Long-Term Functional Outcomes

<p><strong>VinFast Auto Ltd.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) shares traded higher Thursday after the Federal Reserve cut interest rates by 50 basis points (bps) on Wednesday. <strong>The company will report its second-quarter results before Friday's opening bell and host a conference call at 8 a.m. ET to discuss the results.</strong></p>
<h1 class="wp-block-heading"><strong>Here's A <a href="https://www.benzinga.com/markets/equities/24/09/40866380/tesla-china-shines-lucid-gives-peek-into-model-y-rival-ford-eyes-electric-restart-in-india-and-m">Look At What To Know&nbsp;</a></strong></h1>
<p><strong>What Happened:</strong> VinFast Auto shares closed higher Thursday amid a broad <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40944143/wall-street-breaks-records-chipmakers-rally-tesla-hits-2-month-high-as-fed-cut-drives-risk">market rally </a>as investors digested the Fed's larger-than-anticipated interest rate cut which marked the first in more than four years.</p>
<p>The rate cut brings the federal funds rate down to a range of 4.75% to 5% and will reduce the cost of borrowing for companies and consumers.&nbsp;</p>
<p>According to estimates from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, analysts expect the company to report quarterly losses of 21 cents per share and $460.089 million in revenue.&nbsp;</p>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/fintech/24/09/40928342/what-happened-with-sofi-stock-today"><strong>What Happened With SoFi Stock Today?</strong></a></p>
<p><strong>What Else:</strong> Last week, the National Highway Traffic Safety Administration initiated a probe into VinFast's EVs based on complaints from vehicle owners. The probe covered around 3,118 vehicles manufactured in 2023 and 2024, with owners alleging that the vehicles had problems with the &#8220;Lane Keep Assist&#8221; system. </p>
<p>Owners claimed the EVs had difficulty detecting lanes on the roadway and provided improper steering inputs.&nbsp;</p>
<h1 class="wp-block-heading"><strong>Will VFS Stock Go Up?</strong></h1>
<p>When trying to assess whether or not VinFast Auto will trade higher from current levels, it's a good idea to take a look at analyst forecasts.</p>
<p>Wall Street analysts have an average 12-month price target of $8 on VinFast Auto. Of all the analysts covering VinFast Auto, six have positive ratings, no one has a neutral rating and no one has a negative rating.</p>
<p>In the last month, two analysts have adjusted price targets. Here's a look at recent price target changes <a href="https://www.benzinga.com/quote/VFS/analyst-ratings">[Analyst Ratings]</a>. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering VinFast Auto have performed in recent history.</p>
<p>Stocks don't move in a straight line. The average stock market return is approximately 10% per year. VinFast Auto is 43.83% down year-to-date. The average analyst price target suggests the stock could have further upside ahead.</p>
<p>For a broad overview of everything you need to know about VinFast Auto, visit <a href="https://www.benzinga.com/quote/VFS">here</a>. If you want to go above and beyond, there's no better tool to help you do just that than <a href="https://pro.benzinga.com/">Benzinga Pro</a>. Start your free trial today.</p>
<p><strong>VFS Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, VinFast Auto shares ended Thursday's session 2.06% higher at $3.96.&nbsp;</p>
<p><strong>Read Also:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40923038/whats-going-on-with-carnival-stock"><strong>What&#8217;s Going On With Carnival Stock?</strong></a></li>
</ul>
<p><em>Photo: Shutterstock </em></p>


Movers

What's Going On With VinFast Auto Stock?

<p>Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) reported quarterly earnings of $3.90 per share which beat the analyst consensus estimate of $3.63 by 7.44 percent. The company reported quarterly sales of $9.416 billion which beat the analyst consensus estimate of $9.164 billion by 2.76 percent. This is a 7.86 percent increase over sales of $8.730 billion the same period last year.</p>


Earnings

Lennar Q3 2024 Adj. EPS $3.90 Beats $3.63 Estimate, Sales $9.416B Beat $9.164B Estimate

TBNK

In Response To Proposal From Blue Hill Advisors To Acquire Territorial Bancorp, Territorial Reaffirms Board's Commitment To Proposed Merger With Hope Bancorp

KOPN

Kopin shares are trading lower after the company announced a public offering of common stock and pre-funded warrants, size not disclosed.

<p>The 2024 National Football League season enters Week 3 with nine of the 32 teams holding a perfect 2-0 record, including the Kansas City Chiefs, hoping to become the first NFL team to win<a href="https://www.benzinga.com/general/sports-betting/24/07/39752864/bettors-favor-kansas-city-chiefs-for-super-bowl-three-peat-heres-a-look-at-how-states-are-"> three straight Super Bowls.</a></p>
<p>Here's a look at the betting odds and media companies that could benefit in the third week of the 2024 NFL season.</p>
<p><strong>Week 3 Betting Odds:</strong> Week 3 features 16 <a href="https://www.benzinga.com/general/entertainment/24/09/40886493/nfl-games-dominate-week-1-ratings-start-week-2-with-a-bang-here-these-companies-might-benef">NFL games </a>across Thursday, Sunday and Monday and will see two matchups of 2-0 perfect teams.</p>
<p>Here are the week 3 matchups and the betting odds from sportsbook <strong>DraftKings Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with the team's records in parentheses.</p>
<ul>
<li>New England Patriots (1-1) at New York Jets (1-1) -6</li>
<li>Denver Broncos (0-2) at Tampa Bay Buccaneers (2-0) -6.5</li>
<li>Los Angeles Chargers (2-0) at Pittsburgh Steelers (2-0) -1.5</li>
<li>New York Giants (0-2) at Cleveland Browns (1-1) -6.5</li>
<li>Houston Texans (2-0) -2 at Minnesota Vikings (2-0)</li>
<li>Philadelphia Eagles (1-1) at New Orleans Saints (2-0) -2.5</li>
<li>Green Bay Packers (1-1) at Tennessee Titans (0-2) -2</li>
<li>Chicago Bears (1-1) at Indianapolis Colts (0-2) -1.5</li>
<li>Carolina Panthers (0-2) at Las Vegas Raiders (1-1) -5</li>
<li>Miami Dolphins (1-1) at Seattle Seahawks (2-0) -4.5</li>
<li>Detroit Lions (1-1) -3 at Arizona Cardinals (1-1)</li>
<li>Baltimore Ravens (0-2) -1 at Dallas Cowboys (1-1)</li>
<li>San Francisco 49ers (1-1) -7 at Los Angeles Rams (0-2)</li>
<li>Kansas City Chiefs (2-0) -3.5 at Atlanta Falcons (1-1)</li>
<li>Jacksonville Jaguars (0-2) at Buffalo Bills (2-0) -5</li>
<li>Washington Commanders (1-1) at Cincinnati Bengals (0-2) -7.5</li>
</ul>
<p>A quick look at the betting odds shows five of the away teams favored, down from the six away teams favored in week two and up from two away teams favored in the first week.</p>
<p>The third week features the 2-0 matchups between the Chargers and Steelers and the Texans vs. the Vikings. BetMGM's <strong>John Ewing</strong> <a href="https://x.com/johnewing/status/1836214185673248852">notes </a>that in the last 10 years, underdogs are 35-20-1 against the spread when undefeated teams play each other.</p>
<p>None of the Week 3 matchups are between 0-2 teams, which means there could still be nine 0-3 teams after the week is over as these teams fight to get a win on their record.</p>
<p>Bettors may focus on 0-2 teams desperate for a win. Ewing noted that 0-2 teams are 52-33-1 against the spread in Week 3 over the past decade.</p>
<p>Thursday night's game kicks off with a big spread of six points<span style="box-sizing: border-box; margin: 0px; padding: 0px;">, and sports betting reporter <strong>Ben Fawkes</strong> <a href="https://x.com/BFawkes22/status/1836766403648483476" target="_blank" rel="noopener">notes </a>that it will be the first time the Jets are favored against the Patriots in 25 games. This will end</span> the longest active head-to-head streak of two teams against each other.</p>
<p>Sports betting reporter <strong>Evan Abrams</strong> <a href="https://x.com/EvanHAbrams/status/1835526810903138789">notes </a>that underdogs of 6+ points are 8-0 against the spread through the first two weeks, marking the best start for big underdogs in NFL history.</p>
<p><span style="box-sizing: border-box; margin: 0px; padding: 0px;">According to Fawkes, at DraftKings, the most bets on teams against the spread are the Chiefs -3.5 (81% of bets), Saints -2.5 (78%), Bengals -7.5 (77%), Raiders -5.5 (77%), and 49ers -7 (76%)</span>.</p>
<p>Sportsbooks have been<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40885110/draftkings-sportsbooks-could-benefit-from-week-2-nfl-underdogs-winning"> benefitting from underdogs </a>covering the spread and winning outright, and the public is 11-20-1 against the spread through the first two weeks, according to <a href="https://x.com/BFawkes22/status/1836526740220579887">Fawkes</a>.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/general/sports-betting/24/09/40720484/which-4-teams-have-never-reached-the-super-bowl-betting-payouts-if-history-is-made-in-2024">Which 4 Teams Have Never Reached The Super Bowl? Betting Payouts If History Is Made In 2024 NFL Season</a></strong></p>
<p><strong>Media Stocks on Watch: </strong>NFL games are averaging 19.7 million viewers per game through the first two weeks, up 12% year-over-year, as <a href="https://x.com/NFLMedia/status/1836495412649509024">reported </a>by the league. This marks the second-highest average through the second week in league history.</p>
<p>Here are the national primetime television games for the third week of the NFL season:</p>
<ul>
<li>Thursday, Sept. 19, 8:15 p.m. ET: Patriots, Jets on Prime Video, a unit of <strong>Amazon.com Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and NFL+</li>
<li>Sunday, Sept. 22, 8:20 p.m. ET: Chiefs, Falcons on NBC, Peacock, units of<strong> Comcast Corporation </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>)</li>
<li>Monday, Sept. 23, 7:30 p.m. ET: Jaguars, Bills on ESPN, a unit of <strong>The Walt Disney Company </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)</li>
<li>Monday, Sept. 23, 8:15 p.m. ET: Commanders, Bengals on ABC, ESPN+, units of Disney</li>
</ul>
<p>The Sunday 1 p.m. ET and 4 p.m. ET games will be broadcast by<strong> Paramount Global </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) unit CBS and <strong>Fox Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) unit FOX.</p>
<p>Disney could be the big winner for the week with two Monday Night Football games across its networks. Comcast also stands to benefit with a primetime matchup featuring the Chiefs. While<strong> Taylor Swift</strong> could be in attendance to watch boyfriend<strong> Travis Kelce</strong>, the Chiefs remain a popular team for viewership regardless. </p>
<p>The Chiefs&#8217; first two games of the season are the most-watched NFL games, drawing 28 million viewers in Week 1 and 27.9 million in Week 2.</p>
<p>Comcast has two of the top five most watched NFL games through the first two weeks, with CBS, Fox and Disney each having one game on the list.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/sports-betting/24/08/40555085/sports-illustrated-predicts-detroit-lions-to-win-super-bowl-heres-how-much-100-bet-could-p">Sports Illustrated Predicts Detroit Lions To Win Super Bowl: Here&#8217;s How Much $100 Bet Could Pay If History Is Made</a></strong></li>
</ul>
<p>Photo: Shutterstock</p>


Entertainment

Sports Betting

Sports

AMZN

CMCSA

DKNG

FOXA

PARA

PARAA

NFL Week 3 Betting Odds, National TV Games: Can Disney Win With Two Monday Night Football Games? How Many 2-0 Teams Will Stay Perfect?

<p>Biodexa Pharmaceuticals PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts ("ADR") from one (1) ADR representing four hundred (400) ordinary shares, to the new ratio of one (1) ADR representing ten thousand (10,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be October 4,2024.</p>
<p>Pursuant to the Ratio Change, ADR holders will be required on a mandatory basis to surrender their ADRs for cancellation and exchange to receive one (1) new ADR (New CUSIP: 59564R807) for every twenty-five (25) old ADRs (Old CUSIP: 59564R708). No fractional ADRs will be allocated. The aggregate fractions, if any, will be sold and the net proceeds will be distributed to the entitled ADR holder. The Company's Depositary, JP Morgan Chase Bank, N.A. will contact ADR holders and arrange for the exchange of their existing ADRs for new ADRs.</p>


Stock Split

BDRX

Biodexa Pharmaceuticals Announces A Ratio Change On Its ADRs From 1 ADS Representing 400 Ordinary Shares, To The New Ratio Of 1 ADR Representing 10,000 Ordinary Shares (1-For-25) ; Effective Date Of The Ratio Change Is Expected To Be October 4,2024.

Dividends

W. P. Carey Increases Quarterly Dividend From $0.87 To $0.875/Share

<p><strong><u>Guidance</u></strong></p>
<p>The following are the Company&#39;s expected results of its homebuilding and financial services activities for the&nbsp;fourth quarter&nbsp;of 2024:</p>
<table border="0" cellpadding="1" cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
<p>New Orders</p>
</td>
<td colspan="1" rowspan="1">
<p>19,000 - 19,300</p>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<p>Deliveries</p>
</td>
<td colspan="1" rowspan="1">
<p>22,500 - 23,000</p>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<p>Average Sales Price</p>
</td>
<td colspan="1" rowspan="1">
<p>About&nbsp;$425,000</p>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<p>Gross Margin % on Home Sales</p>
</td>
<td colspan="1" rowspan="1">
<p>Flat with&nbsp;Q3</p>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<p>S,G&amp;A as a % of Home Sales</p>
</td>
<td colspan="1" rowspan="1">
<p>6.7%&nbsp;-&nbsp;6.8%</p>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<p>Financial Services Operating Earnings</p>
</td>
<td colspan="1" rowspan="1">
<p>$140 million</p>
</td>
</tr>
</tbody>
</table>


Guidance

Lennar Sees Q4 Average Sales Price ~$425,000; Financial Services Operating Earnings $140M

Lennar shares are trading higher after the company reported better-than-expected Q3 financial results.

<p>Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) reported quarterly earnings of $4.26 per share which beat the analyst consensus estimate of $3.68 by 15.76 percent.  The company reported quarterly sales of $9.416 billion which beat the analyst consensus estimate of $9.164 billion by 2.76 percent.  This is a 7.86 percent increase over sales of $8.730 billion the same period last year.</p>


Earnings Beats

Lennar Q3 2024 GAAP EPS $4.26 Beats $3.68 Estimate, Sales $9.416B Beat $9.164B Estimate

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Morgan Stanley</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MS, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for <strong>Morgan Stanley</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 25% bullish and 50%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $48,850, and 7, calls, for a total amount of $497,736.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $80.0 to $105.0 for Morgan Stanley during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Morgan Stanley stands at 5764.14, with a total volume reaching 1,318.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Morgan Stanley, situated within the strike price corridor from $80.0 to $105.0, throughout the last 30 days.</p>
<h3>Morgan Stanley Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726777913_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.85</td>
<td>$6.75</td>
<td>$6.8</td>
<td>$100.00</td>
<td>$125.8K</td>
<td>14.8K</td>
<td style="text-align: right;">206</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$23.0</td>
<td>$22.9</td>
<td>$22.9</td>
<td>$80.00</td>
<td>$103.0K</td>
<td>56</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$105.00</td>
<td>$84.0K</td>
<td>7.8K</td>
<td style="text-align: right;">211</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.85</td>
<td>$100.00</td>
<td>$57.3K</td>
<td>3.5K</td>
<td style="text-align: right;">379</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.45</td>
<td>$8.35</td>
<td>$8.45</td>
<td>$97.50</td>
<td>$50.7K</td>
<td>220</td>
<td style="text-align: right;">63</td>
</tr>
</tbody>
</table>
</p>
<h3>About Morgan Stanley</h3>
<p>Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.</p>
<p>Having examined the options trading patterns of Morgan Stanley, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Morgan Stanley's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 9,054,366, the MS's price is up by 1.44%, now at $100.73. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
<h3>Expert Opinions on Morgan Stanley</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $105.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Goldman Sachs lowers its rating to Neutral with a new price target of $105.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Morgan Stanley, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Looking At Morgan Stanley's Recent Unusual Options Activity

<p>Deep-pocketed investors have adopted a bearish approach towards Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MPC usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Marathon Petroleum. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 36% leaning bullish and 54% bearish. Among these notable options, 9 are puts, totaling $484,470, and 2 are calls, amounting to $91,160.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $155.0 to $155.0 for Marathon Petroleum over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Marathon Petroleum's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Marathon Petroleum's substantial trades, within a strike price spectrum from $155.0 to $155.0 over the preceding 30 days.</p>
<h3>Marathon Petroleum Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726777908_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MPC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$21.6</td>
<td>$20.85</td>
<td>$21.6</td>
<td>$155.00</td>
<td>$105.8K</td>
<td style="text-align: right;">431</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>MPC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$22.25</td>
<td>$20.8</td>
<td>$21.8</td>
<td>$155.00</td>
<td>$95.9K</td>
<td style="text-align: right;">431</td>
<td style="text-align: right;">144</td>
</tr>
<tr>
<td>MPC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$21.9</td>
<td>$20.6</td>
<td>$21.9</td>
<td>$155.00</td>
<td>$61.3K</td>
<td style="text-align: right;">431</td>
<td style="text-align: right;">48</td>
</tr>
<tr>
<td>MPC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$22.4</td>
<td>$20.6</td>
<td>$21.9</td>
<td>$155.00</td>
<td>$52.5K</td>
<td style="text-align: right;">431</td>
<td style="text-align: right;">72</td>
</tr>
<tr>
<td>MPC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$24.8</td>
<td>$24.25</td>
<td>$24.8</td>
<td>$155.00</td>
<td>$49.6K</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">20</td>
</tr>
</tbody>
</table>
</p>
<h3>About Marathon Petroleum</h3>
<p>Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 3.0 million barrels per day. Its Dickinson, North Dakota, facility produces 184 million gallons a year of renewable diesel. Its Martinez, California, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed master limited partnership, MPLX.</p>
<h3>Where Is Marathon Petroleum Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,110,663, the price of MPC is up by 1.02%, reaching $166.35.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 47 days from now.</li>
</ul>
<h3>What The Experts Say On Marathon Petroleum</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $187.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Marathon Petroleum, targeting a price of $182.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Neutral rating for Marathon Petroleum, targeting a price of $193. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Marathon Petroleum, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


What the Options Market Tells Us About Marathon Petroleum

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Carnival</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CCL, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 16 options trades for <strong>Carnival</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 37% bullish and 50%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $123,686, and 15, calls, for a total amount of $1,266,723.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $7.5 to $30.0 for Carnival during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Carnival options trades today is 7897.0 with a total volume of 21,485.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Carnival's big money trades within a strike price range of $7.5 to $30.0 over the last 30 days.</p>
<h3>Carnival Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726777903_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$0.69</td>
<td>$0.67</td>
<td>$0.67</td>
<td>$20.00</td>
<td>$335.0K</td>
<td>15.6K</td>
<td>5.3K</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$3.0</td>
<td>$2.99</td>
<td>$3.0</td>
<td>$16.00</td>
<td>$299.7K</td>
<td>1.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.5</td>
<td>$7.3</td>
<td>$7.45</td>
<td>$25.00</td>
<td>$123.6K</td>
<td>701</td>
<td>167</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$11.55</td>
<td>$11.4</td>
<td>$11.5</td>
<td>$7.50</td>
<td>$115.0K</td>
<td>5.0K</td>
<td>100</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$3.75</td>
<td>$3.7</td>
<td>$3.71</td>
<td>$15.00</td>
<td>$74.2K</td>
<td>2.1K</td>
<td>204</td>
</tr>
</tbody>
</table>
</p>
<h3>About Carnival</h3>
<p>Carnival is the largest global cruise company, with 92 ships in service at the end of fiscal 2023. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&amp;O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It's currently folding its P&amp;O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted nearly 13 million guests in 2019, prior to covid-19, a level it reached again in 2023.</p>
<p>After a thorough review of the options trading surrounding Carnival, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Carnival</h3>
<ul>
<li>With a trading volume of 25,781,477, the price of CCL is up by 2.18%, reaching $18.76.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 11 days from now.</li>
</ul>
<h3>Expert Opinions on Carnival</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $25.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Mizuho persists with their Outperform rating on Carnival, maintaining a target price of $25. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Carnival with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Looking At Carnival's Recent Unusual Options Activity

GEOS

Geospace Technologies Announces Realignment Into Three New Business Segments: Smart Water, Energy Solutions, And Intelligent Industrial

<p><i>Candidates are invited to explore full- and part-time seasonal opportunities supporting Macy's, Inc.'s portfolio of nameplates, including Macy's, Bloomingdale's and Bluemercury</i></p>
<p><i>Holiday hiring events will take place nationwide at all stores and distribution centers throughout the season, with the first on Thursday, September 26</i></p>
<p>Macy's, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) today announced plans to hire more than 31,500 full- and part-time seasonal positions this upcoming holiday season at its Macy's, Bloomingdale's and Bluemercury stores, as well as its distribution centers. Macy's, Inc. offers several convenient hiring experiences for candidates including an online application process that takes as little as five minutes, with most job offers made within 48 hours. Additionally, the company is holding four nationwide in-person holiday hiring events at all stores and supply chain locations. Times may vary by location.</p>
<ul>
<li>September 26</li>
<li>October 24</li>
<li>November 21</li>
<li>December 4</li>
</ul>


Management

Macy's Gears Up To Hire For More Than 31,500 Seasonal Positions; Holiday Hiring Events Will Take Place Nationwide At All Stores And Distribution Centers Throughout The Season, With The First On Thursday, September 26

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNGGF"><strong>Cann Gr</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNGGF#OTC">CNGGF</a>) shares closed up 346.42% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BLGVF"><strong>Belgravia Hartford Cap</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 53.73% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CBDY"><strong>Target Group</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 45.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/SOLCF"><strong>SOL Glb Inv</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 35.97% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/MGWFF"><strong>Maple Leaf Green World</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed up 24.59% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/RMHB"><strong>Rocky Mountain High</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 11.11% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO"><strong>Urban-gro</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 9.56% at $1.39</li>
<li><a href="https://www.benzinga.com/quote/XXII"><strong>22nd Century Group</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 9.30% at $0.26</li>
<li><a href="https://www.benzinga.com/quote/CNPOF"><strong>RIV Capital</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed up 8.50% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/FUAPF"><strong>Global Compliance</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 7.22% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/GENE"><strong>Genetic Technologies</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) shares closed up 5.53% at $0.81</li>
<li><a href="https://www.benzinga.com/quote/CRBP"><strong>Corbus Pharmaceuticals</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 4.80% at $51.70</li>
<li><a href="https://www.benzinga.com/quote/MXC"><strong>Mexco Energy</strong></a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed up 4.52% at $11.96</li>
<li><a href="https://www.benzinga.com/quote/FFNTF"><strong>4Front Ventures</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 3.98% at $0.05</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LBUY"><strong>Leafbuyer Techs</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 70.00% at $0.0006</li>
<li><a href="https://www.benzinga.com/quote/BMMJ"><strong>Body and Mind</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed down 29.89% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/LMLLF"><strong>Pharmadrug</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 26.78% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/KAYS"><strong>Kaya Holdings</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 18.02% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/LVRLF"><strong>CordovaCann</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 12.82% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/CURR"><strong>Currenc Group</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 4.03% at $3.01</li>
<li><a href="https://www.benzinga.com/quote/CNTMF"><strong>Cansortium</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 3.53% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/NWVCF"><strong>EnWave</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 3.19% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/CPHRF"><strong>Cipher Pharmaceuticals</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed down 3.11% at $11.06</li>
<li><a href="https://www.benzinga.com/quote/CVSI"><strong>CV Sciences</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 3.04% at $0.04</li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cannabis

BLGVF

BMMJ

CBDY

CNGGF

CNPOF

CNTMF

CPHRF

CRBP

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

FFNTF

FUAPF

GENE

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

LVRLF

MGWFF

NWVCF

RMHB

SOLCF

UGRO

XXII

Bullish Sentiment Across The Cannabis Space - Check Full Movers For September 19, 2024

Atossa Therapeutics appoints Heather Rees as chief financial officer

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>By now, you&rsquo;re well aware of the dangers of trading <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> with upside. But as a reminder, not only will you find a disclaimer at the tail-end of this article about penny stock dangers, but here&rsquo;s what the U.S. SEC says:</p>



<p>&ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/"></a>Penny stocks&nbsp;may trade infrequently &mdash; which means that it may be difficult to sell penny stock shares once you have them. Because it may also be difficult to find quotations for penny stocks, they may be impossible to accurately price. Investors in penny stock[s] should be prepared for the possibility that they may lose their whole investment.&rdquo;</p>



<p>Sure, penny stocks are attractive at such low prices. But they&rsquo;re also dangerous.</p>



<p>If you understand the risks and want to invest in them anyway, investigate the stocks where insiders are putting their money where their mouth is. After all, if they&rsquo;re putting up their own money, they must have a good deal of confidence in their stock.</p>



<p>Here are three potential penny stock moonshots you may want to consider.</p>



<h2>Aurora Innovation (AUR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/01/car-1600-300x169.jpg" alt="the front wheels of a series of cars in a line"><div>Source: lumen-digital / Shutterstock.com</div></div><p>The last time I highlighted an opportunity in <strong>Aurora Innovation</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aur-stock-quote/"><strong>AUR</strong></a>), <strong>Uber Technologies</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/uber-stock-quote/"><strong>UBER</strong></a>) had just bought about $75 million worth of the AUR stock. Plus,&nbsp;Volvo Autonomous Solutions just unveiled&nbsp;<strong>AB Volvo&rsquo;s&nbsp;</strong>(OTCMKTS:<a href="https://investorplace.com/stock-quotes/vlvly-stock-quote/"><strong>VLVLY</strong></a>) first-ever production-ready autonomous truck in Las Vegas &mdash; using Aurora Innovation technology.&nbsp;</p>



<p>That was on June 5, as shares of AUR traded at around $2.15. Today, it&rsquo;s up to $2.81, where it&rsquo;s still a long-term buying opportunity. </p>



<p>Helping, Aurora&rsquo;s involvement with autonomous trucking gives it exposure to a potential <a href="https://www.fortunebusinessinsights.com/autonomous-truck-market-103590#">$76 billion market opportunity</a> by 2032 from $35.51 billion.</p>



<p>Also, while the company didn&rsquo;t report any revenue for its recent quarter, its earnings per share loss of 11 cents was still better than estimates for a loss of 14 cents. Even better, George Soros&rsquo; fund recently picked up about 4.5 million shares of AUR in late March. Jim Simons&rsquo; <strong>Renaissance Technologies</strong> also picked up 477,900 shares in late March.</p>



<h2>Globalstar (GSAT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/09/gsat1600-300x169.png" alt="In this photo illustration the Globalstar (GSAT) logo seen displayed on a smartphone screen"><div>Source: rafapress / Shutterstock.com</div></div><p>We can also look at oversold shares of telecommunications infrastructure company, <strong>Globalstar</strong> (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/gsat-stock-quote/"><strong>GSAT</strong></a>), which currently trades at $1.07. Fueling interest in the stock, director <a href="https://www.investing.com/news/company-news/globalstar-executive-monroe-james-iii-buys-48-million-in-company-stock-93CH-3503747#:~:text=On%20June%2028%2C%202024%2C%20Monroe,known%20as%20XCom%20Labs%2C%20Inc.">James Monroe III bought 4.51 million shares of GSAT</a> for about $4.8 million on July 1.</p>



<p>Helping, <strong>Apple</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aapl-stock-quote/"><strong>AAPL</strong></a>) recently said it would expand the capabilities of satellite messaging on the iPhone. &ldquo;The new iOS 18 update will broaden the availability beyond emergency messaging, and Messages via satellite will be an option when cellular and Wi-Fi connections are not available,&rdquo; according to <a href="https://www.satellitetoday.com/connectivity/2024/06/11/apple-expands-satellite-messaging-capabilities-with-ios-18/">SatelliteToday.com</a>.&nbsp;</p>



<p>That&rsquo;s great news for GSAT considering it partnered with Apple for the satellite connectivity components.<strong>&nbsp;</strong>Even better, funds such as <a href="https://hedgefollow.com/stocks/GSAT">Jim Simons&rsquo; Renaissance Technologies</a> recently bought 156,430 shares of GSAT. Israel Englander&rsquo;s Millennium Management also bought another 38,230 shares.</p>



<p>With earnings, while its first quarter EPS loss of a penny was just in line with estimates, its revenue of $56.48 million did beat by $1.74 million.&nbsp;</p>



<h2>Atossa Genetics (ATOS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/biopharma-1600-300x169.jpg" alt="a scientist with protective equipment and microscope in a lab, OBSV stock"><div>Source: luchschenF / Shutterstock.com</div></div><p>The first time I mentioned&nbsp;<strong>Atossa Genetics</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/atos-stock-quote/"><strong>ATOS</strong></a>), it traded at 75 cents on <a href="https://investorplace.com/2023/04/the-3-best-biotech-stocks-under-1-to-buy-for-april/">April 4, 2023</a>. At the moment, it&rsquo;s up to $1.20, and is still an attractive buy as it pivots from support.</p>



<p>The company recently posted encouraging data from a Phase 2 study of its drug (<span>Z</span>)-endoxifen as a neoadjuvant treatment for breast cancer.</p>



<p>As noted by the company, the 40mg EVANGELINE data is &ldquo;extremely encouraging as it shows that (<span>Z</span>)-endoxifen can not only stop ER+ breast cancer from growing, but it can also shrink or eliminate the tumor, as measured by MRI imaging,&rdquo; <a href="https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-and-quantum-leap-healthcare-announce-i-spy-2#:~:text=%E2%80%9CData%20recently%20presented%20at%20the,MRI%20imaging%2C%E2%80%9D%20said%20Dr.">said Dr. Steven Quay, Atossa&rsquo;s President and Chief Executive Officer</a>.</p>



<p>Even better, funds have been aggressively buying ATOS. At the end of March, for example, <a href="https://hedgefollow.com/stocks/ATOS">Israel Englander&rsquo;s Millennium Management</a> increased its stake in ATOS by 2,040%. Ken Griffin&rsquo;s Citadel Advisors increased its stake by nearly 1,280%. Jim Simons&rsquo; Renaissance Technologies increased its stake by about 8% with the addition of 102,100 shares.</p>



<h2></h2>



<p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong>&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More:</strong>&#8239;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, Ian Cooper&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned.&nbsp;The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=quotemedia&amp;utm_medium=referral">Publishing Guidelines</a>.&nbsp;</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or<br>indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/3-penny-stock-moonshots-with-300-upside-potential-by-2025/">3 Penny Stock Moonshots with 300%+ Upside Potential by 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Penny Stock Moonshots with 300%+ Upside Potential by 2025

Executive reshuffles: NIO, Pfizer and Spirit Airlines in focus

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That&rsquo;s because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results.&nbsp;</p>



<p>Thus, these stocks, especially when trading at low prices, have the potential to rapidly increase in value. In such cases, a frenzy can quickly spike the stock, leading to a relatively short-term situation with above-average returns.&nbsp; However, it is important to keep in mind that just as quickly as these stocks rise they can fall as a result of disappointment or regulatory failures.</p>



<p>That said, if investors understand the medical potential of the drug developer they are investing in, the risk can be more palatable. As such, this article will aim to look at three cheap drug developer stocks whose products could rapidly raise their value.</p>



<h2>Scynexis (SCYX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p>As far as cheap drug developers go, <strong>Scynexis </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/scyx-stock-quote/"><strong>SCYX</strong></a>) didn&rsquo;t always fall into that category. Rather, the company once traded over $100 and today is down 98% since its initial public offering in 2014. There have been several reasons for this between its recalls and deal restructurings with <strong>GSK </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/gsk-stock-quote/"><strong>GSK</strong></a>). Beyond this, its product pipeline tends to fly under the radar for many investors as its focus on anti-fungal treatments is often misunderstood.</p>



<p>Yet, due to the biology of fungi, treating them is an incredibly difficult feat that could be key to reducing mortality in immunocompromised patients and even preventing a future <a href="https://www.medscape.com/viewarticle/could-fungal-infection-cause-future-pandemic-2024a1000a39?form=fpf">pandemic</a>. Its current fungal genus that it focuses on is<strong> </strong><em>Candida </em>which has several strains and can present in several regions in the body.&nbsp;</p>



<p>While the company already has two effective treatments co-developed and brought to market with GSK, its current experimental <em>Candida </em>treatment called <a href="https://www.scynexis.com/our-science/pipeline/">SCY-247</a> could be a future catalyst, as it could potentially treat drug-resistant strains of the fungus, which are becoming <a href="https://www.cdc.gov/candidiasis/antimicrobial-resistance/index.html#:~:text=Antimicrobial%2Dresistant%20invasive%20candidiasis%20is,bloodstream%20infection%20in%20the%20U.S.">more common</a>.</p>



<h2>Atai Life Sciences (ATAI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/05/psychedelics-4-300x169.jpg" alt="Mushrooms next to various medical tools; mushrooms in a pill container to represent psychedelic treatments"><div>Source: Shutterstock</div></div><p><strong>Atai Life Sciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/atai-stock-quote/"><strong>ATAI</strong></a></span>) is currently expanding its focus on alternative mental health therapies through an innovative approach to psychedelic compound research. Its pipeline features a range of drugs based on psychedelic substances such as ketamine, psilocybin and <a href="https://www.europeanpharmaceuticalreview.com/news/178880/major-study-on-dmt-shows-promise-for-depression/">DMT</a>. While these compounds are often associated with recreational use, emerging peer-reviewed studies suggest they contain considerable potential for treating mental health disorders.</p>



<p>The company&rsquo;s current flagship drug, COMP360, is currently in Phase-3 clinical trials in collaboration with <strong>Compass Pathways </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/cmps-stock-quote/"><strong>CMPS</strong></a>). COMP360 has also shown incredible promise in treating individuals suffering from major depressive disorder who are resistant to other forms of antidepressants. <a href="https://ir.compasspathways.com/node/8326/pdf">Over 30% </a>of drug-resistant patients saw remission during the 12-week trial period, suggesting breakthrough therapy potential.</p>



<p>Given its current trading price at a 93% discount from its initial public offering, Atai Life Sciences is one of those cheap drug developer stocks investors should not pass up. That&rsquo;s because any positive developments regarding its drug candidates could significantly boost the company&rsquo;s value.</p>



<h2>Atossa Therapeutics (ATOS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/biopharma-1600-300x169.jpg" alt="a scientist with protective equipment and microscope in a lab, OBSV stock"><div>Source: luchschenF / Shutterstock.com</div></div><p>Unlike many biotechnology companies that prioritize developing treatments for existing diseases, <strong>Atossa Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/atos-stock-quote/"><strong>ATOS</strong></a>) focuses on disease prevention. One of its most promising drugs, <a href="https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-announces-last-patient-last-dose-its-phase-2">Karisma-Endoxifen</a>, finished its most recent round of clinical trials. This innovative drug aims to reduce breast tissue density, thereby lowering the risk of developing cancer.</p>



<p>The results of these trials are expected soon, and a positive outcome could significantly enhance Atossa&rsquo;s stock potential. Additionally, Atossa&rsquo;s dedicated focus on breast cancer provides stability to its stock, as the company channels all its resources into combating this single disease. Alongside its pharmaceutical treatments, the company has also begun supporting a trial for <a href="https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-announces-support-clinical-study-testing-new">artificial intelligence-based diagnosis</a> of breast cancer.</p>



<p>Pair these innovations with a relatively flat and consistent trading pattern, combined with the potential for promising trial results, and Atossa earns a buy rating. Furthermore, its low stock price means a small investment could go a long way.</p>



<p><em>On the date of publication, Viktor Zarev&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em></p>
<div><p>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/3-dirt-cheap-drug-developers-with-blockbuster-potential/">3 Dirt-Cheap Drug Developers With Blockbuster Potential</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Dirt-Cheap Drug Developers With Blockbuster Potential

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report), retaining the price target of $6.0...

Atossa Therapeutics: A Promising Buy Amid Anticipated Clinical Breakthroughs

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Atossa Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/atos-stock-quote/"><strong>ATOS</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Atossa Therapeutics reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -6 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/atos-stock-earnings-atossa-therapeutics-for-q2-of-2024/">ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024

Atossa Therapeutics GAAP EPS of -$0.05 in-line

Atossa Therapeutics (ATOS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCart...

Atossa Therapeutics: A Promising Buy in Oncology with Strong Financials and Upcoming Trial Milestones

Atos SE's ($FR:ATO) shares dropped over 3% as of writing today after the company reduced its financial targets through 2027, citing weakened sales ...

Atos Shares Drop on Reduced Financial Targets

AMAT

ASTS

ASXC

ATAI

BABA

BATL

BEEM

BEKE

BLDP

BLUE

CARA

CATX

CMPS

COCP

CSCO

CTRM

ESPR

FOSL

FWRD

GLNG

GOEV

GOLD

GRAB

GSAT

HUYA

JAGX

KNDI

LITE

MDAI

MIRA

MMAT

MNDY

MTEX

NNDM

NVDA

OGEN

OUST

PSFE

RRAC

RYAN

SACH

SAVE

SCYX

SMID

STNE

TAYD

TCEHY

TCRT

VLVLY

VUZI

WKHS

Press Releases

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Health Care

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Legal

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Cabaletta Bio

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Atossa Therapeutics

Atossa Therapeutics (ATOS) Forecast

Atossa Therapeutics (NASDAQ:ATOS) Stock, Quote.Headers.trade-ideas